Literature DB >> 6861089

Carcinoma in situ of the urinary bladder with and without associated vesical neoplasms.

G R Prout, P P Griffin, J J Daly, N M Heney.   

Abstract

Of 99 patients who had carcinoma-in situ (TIS) at least once between 1970 and 1980, 84 were subjected to detailed analysis and pathologic review. They may be classified into four groups: (Group 1) 14 patients, who presented with invasive bladder carcinoma (TCC) associated with TIS; (Group 2) 15 patients who, subsequent to the diagnosis of TIS with or without another superficial TCC developed muscle invasion (12 patients) or metastases without muscle invasion (three patients); (Group 3) 29 patients who underwent cystectomy for superficial TCC (Ta or T1, or TIS alone). Twenty (69%) had extravesical superficial extension. Two patients developed metastases subsequent to undergoing cystectomy; and (Group 4) 26 patients with TIS proven at least once who have not developed muscle invasion, metastases nor have undergone cystectomy. Nineteen had previous non-TIS superficial TCC. All patients in Groups 2 and 4 were treated conservatively (TUR +/- intravesical chemotherapy) when the initial diagnosis of TIS was made. Twelve patients in Group 3 underwent cystectomy within a month of the diagnosis of TIS. When 38 patients found to have TIS in association with the first diagnosis of superficial transitional cell carcinoma of the bladder were compared with 32 patients who had TIS diagnosed subsequent to their initial diagnosis of transitional cell carcinoma, the former group fared significantly worse (P less than 0.01) in regard to muscle invasion, metastases, or clinical indications for cystectomy.

Entities:  

Mesh:

Year:  1983        PMID: 6861089     DOI: 10.1002/1097-0142(19830801)52:3<524::aid-cncr2820520324>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Clinical outcome of primary versus secondary bladder carcinoma in situ.

Authors:  Daher C Chade; Shahrokh F Shariat; Ari Adamy; Bernard H Bochner; S Machele Donat; Harry W Herr; Guido Dalbagni
Journal:  J Urol       Date:  2010-06-17       Impact factor: 7.450

2.  Possible factors affecting response to intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder: a multivariate analysis.

Authors:  M Takashi; S Katsuno; H Yuba; S Ohshima; K Wakai; Y Ohno
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

3.  Intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy for carcinoma in situ of the bladder.

Authors:  M Takashi; T Shimoji; T Murase; T Sakata; T Sobajima; Y Suzuki
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

4.  The value of tumour spread, grading and growth pattern as morphological predictive parameters in bladder carcinoma. A critical revision of the 1987 TNM classification.

Authors:  J C Angulo; J I Lopez; N Flores; J D Toledo
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Clinical assessment of carcinoma in situ of the human urinary bladder.

Authors:  H Tsujihashi; A Nakanishi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

6.  Intravesical combination chemotherapy with mitomycin C and doxorubicin for superficial bladder cancer: a randomized trial of maintenance versus no maintenance following a complete response.

Authors:  I Fukui; K Kihara; H Sekine; Y Tachibana; T Kawai; D Ishiwata; H Oshima
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  An ultrastructural and morphometric study of bladder tumours (III).

Authors:  A F Smith
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985

8.  Flat in situ carcinoma of the bladder: cytological examination of urine in diagnosis, follow up, and assessment of response to chemotherapy.

Authors:  W J Highman
Journal:  J Clin Pathol       Date:  1988-05       Impact factor: 3.411

9.  Whole bladder wall photodynamic therapy for refractory carcinoma in situ of the bladder.

Authors:  T Uchibayashi; K Koshida; K Kunimi; H Hisazumi
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

Review 10.  Biologic response modifiers in the management of superficial bladder cancer.

Authors:  S Serels; J Fleischmann
Journal:  World J Urol       Date:  1997       Impact factor: 3.661

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.